← Back to Home

Moderna shifts course on norovirus vaccine development: Phase 3 interim analysis misses threshold, no additional cohort this quarter

Moderna had planned to continue evaluating the vaccine by enrolling an additional cohort, but will now first discuss next steps with regulators. mRNA-1403 remains in its Phase 3 pipeline, but its development path remains unclear.

By SURL BioNews

Vaccine development still faces a hurdle in preventing vomiting and diarrhea caused by norovirus. Moderna announced on November 6 that an interim analysis of the Phase 3 trial of its vaccine candidate mRNA-1403 did not meet the statistical threshold for early success. The company decided not to enroll an additional cohort this quarter and will discuss the path forward with health regulators.

The key development is a change in the company's plans. According to Fierce Biotech, Moderna disclosed as early as July this year that the interim analysis had missed its threshold, but still intended at the time to enroll another group of participants. The company has now withdrawn that plan and will be able to outline its next steps only after discussions with regulators.

The Phase 3 study of mRNA-1403 is designed to assess whether the vaccine can prevent acute gastroenteritis caused by norovirus infection in adults. According to the study description published by the UK's Health Research Authority, the trial uses a randomized, placebo-controlled design, enrolls adults aged 18 and older, and monitors infections, gastroenteritis symptoms, and health status after vaccination. The central question is whether vaccination can reduce disease, beyond simply inducing an immune response.

An interim analysis examines accumulated evidence under prespecified rules before a study is completed. Missing the threshold for “early success” means that this analysis did not provide sufficient evidence to declare success early; it does not directly mean that a final analysis has established that the vaccine is ineffective. The company's announcement and presentation did not provide an estimate of protective efficacy, the distribution of cases, or detailed statistical results, making it impossible to determine from this information why the threshold was missed.

Moderna's financial results presentation released the same day continued to list mRNA-1403 as a Phase 3 program. The decision not to enroll an additional cohort this quarter therefore cannot automatically be interpreted as termination of the entire program. However, the original plan to continue accumulating evidence by enrolling additional participants has changed, and the company has not announced an alternative plan or a new timeline.

The decision also comes as Moderna continues to reduce research and development spending. The company's third-quarter research and development expenses were $583 million, down 27% from the same period last year, primarily due to the completion or winding down of certain late-stage infectious disease studies and improved operational efficiency. This overall decline cannot be attributed entirely to the norovirus program. For mRNA-1403, the most critical information ahead will be the complete efficacy data and regulators' views on the evidence required for further development.

References

  1. Fierce Biotech
  2. Moderna, Inc. (SEC filing)
  3. Moderna, Inc. (presentation hosted by 6ix)